Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Giuliani

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Journal of Thrombosis and Haemostasis : JTH|May 13, 2020
Thrombin generation predicts early recurrence in breast cancer patientsMarina Marchetti, Cinzia Giaccherini, Giovanna Masci, et al.
Frontiers in Digital Health|June 15, 2026
Best practices and challenges in executing large scale pilots for eHealth deployment and managing innovation: the GATEKEEPER experienceDavide Piaggio, Jordi de Batlle, Alba M Gallego Montejo, et al.
Therapeutic Advances in Medical Oncology|August 28, 2020
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i>-mutated metastatic colorectal cancer: the REVOLUTION study protocolAntonio Avallone, Maria Carmela Piccirillo, Elena Di Gennaro, et al.
The Lancet. Oncology|November 18, 2024
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trialGiovanni Randon, Sara Lonardi, Matteo Fassan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia MeridionaleGiuseppe Colucci, Vittorio Gebbia, Giancarlo Paoletti, et al.
Journal of Medical Internet Research|June 28, 2023
GATEKEEPER's Strategy for the Multinational Large-Scale Piloting of an eHealth Platform: Tutorial on How to Identify Relevant Settings and Use CasesJordi de Batlle, Ivan D Benítez, Anna Moncusí-Moix, et al.
BMC Cancer|March 30, 2019
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialMaria Di Bartolomeo, Monica Niger, Federica Morano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2015
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Josef Thaler, Richard Greil, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Journal of Thrombosis and Haemostasis : JTH|May 13, 2020
Thrombin generation predicts early recurrence in breast cancer patientsMarina Marchetti, Cinzia Giaccherini, Giovanna Masci, et al.
Frontiers in Digital Health|June 15, 2026
Best practices and challenges in executing large scale pilots for eHealth deployment and managing innovation: the GATEKEEPER experienceDavide Piaggio, Jordi de Batlle, Alba M Gallego Montejo, et al.
Therapeutic Advances in Medical Oncology|August 28, 2020
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i>-mutated metastatic colorectal cancer: the REVOLUTION study protocolAntonio Avallone, Maria Carmela Piccirillo, Elena Di Gennaro, et al.
The Lancet. Oncology|November 18, 2024
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trialGiovanni Randon, Sara Lonardi, Matteo Fassan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia MeridionaleGiuseppe Colucci, Vittorio Gebbia, Giancarlo Paoletti, et al.
Journal of Medical Internet Research|June 28, 2023
GATEKEEPER's Strategy for the Multinational Large-Scale Piloting of an eHealth Platform: Tutorial on How to Identify Relevant Settings and Use CasesJordi de Batlle, Ivan D Benítez, Anna Moncusí-Moix, et al.
BMC Cancer|March 30, 2019
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialMaria Di Bartolomeo, Monica Niger, Federica Morano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2015
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Josef Thaler, Richard Greil, et al.
Pageof 12